Blazing a new TRAIL in hematopoietic cell transplantation.

Published

Journal Article

There is a ying/yang to most biological therapies, and the balance of efficacy versus toxicity is delicate and sometimes difficult to achieve in favor of the patients. When the therapeutic window is wide, these therapies can be used in the majority of patients, but when the therapeutic window is narrow, the decision to proceed must be carefully balanced with a thoughtful risk-benefit analysis. In this issue of the JCI, Ghosh et al. tackle one of the major obstacles in hematopoietic cell transplantation (HCT) technology: balancing the beneficial antitumor effect with the harmful anti-host effect.

Full Text

Duke Authors

Cited Authors

  • Chao, N

Published Date

  • June 2013

Published In

Volume / Issue

  • 123 / 6

Start / End Page

  • 2362 - 2363

PubMed ID

  • 23676458

Pubmed Central ID

  • 23676458

Electronic International Standard Serial Number (EISSN)

  • 1558-8238

Digital Object Identifier (DOI)

  • 10.1172/JCI69909

Language

  • eng

Conference Location

  • United States